Cialis vs Alprostadil (Caverject/MUSE): What to Do When One Fails

How These Two Drugs Actually Work

Tadalafil and alprostadil occupy entirely different spots in the erection pathway. Understanding that difference explains why switching from one to the other often succeeds.

Tadalafil: Dependent on Your Own Nitric Oxide

Tadalafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP inside penile smooth muscle cells. When PDE5 is blocked, cyclic GMP accumulates, smooth muscle relaxes, and blood flows into the corpus cavernosum. The catch: this entire cascade depends on sexual stimulation releasing nitric oxide (NO) in the first place. Men with diabetic autonomic neuropathy, radical prostatectomy nerve damage, or severe vascular disease often produce little or no NO, so tadalafil has nothing to amplify. A 20 mg dose of tadalafil in those men may accomplish very little regardless of how correctly it is taken. FDA labeling for Cialis (tadalafil) confirms that the drug requires sexual stimulation as a prerequisite for response.

Alprostadil: Bypasses the Nitric Oxide Step Entirely

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2 and EP3 receptors on smooth muscle cells and directly stimulates adenylyl cyclase, raising intracellular cyclic AMP. Smooth muscle relaxes without waiting for NO. This mechanism works even when nerves are damaged and NO synthesis is absent, which is precisely why alprostadil rescues patients who fail oral therapy. Linet and Ogrinc (NEJM, 1996; N=296) demonstrated that intracavernosal alprostadil produced erections sufficient for intercourse in 94.4% of injection attempts versus 13.6% with placebo, a difference that held across diabetic and post-prostatectomy subgroups.

Efficacy: What the Clinical Evidence Shows

Tadalafil Response Rates

In the key tadalafil trials, the 20 mg on-demand dose improved the erectile function domain of the International Index of Erectile Function (IIEF-EF) by approximately 8 to 9 points over placebo, and successful intercourse attempts were reported in roughly 75% of attempts versus 32% on placebo. Brock et al. (J Urol, 2002; N=1,112) showed that tadalafil 20 mg achieved a mean IIEF-EF score of 22.6 at endpoint, compared with 13.7 for placebo (P<0.0001). Responder rates fell substantially in high-risk subgroups: men with insulin-dependent diabetes showed approximately 56% success, versus roughly 81% in the overall population.

Alprostadil Response Rates

Caverject (intracavernosal) and MUSE (intraurethral) carry different efficacy ceilings. Caverject consistently outperforms MUSE in direct comparisons, but both outperform placebo substantially. Linet and Ogrinc (NEJM, 1996) reported that 87% of men self-injecting alprostadil at home achieved successful intercourse during at least one of the three in-home study periods. MUSE data from its key trial showed 64.9% of men had at least one successful intercourse attempt versus 18.6% with placebo. For men who specifically failed an oral PDE5 inhibitor, published series place the intracavernosal alprostadil response rate between 70% and 85%.

Head-to-Head Context

No large randomized trial has directly compared tadalafil to alprostadil as a primary endpoint. The available evidence comes from sequential-therapy and rescue studies. Across those studies, the consistent finding is that prior PDE5 failure does not meaningfully reduce the probability of alprostadil response, because the two mechanisms are independent. Switching is therefore clinically rational rather than an act of desperation.

Why Cialis Fails: The Five Most Common Reasons

Not every man who fails tadalafil has pharmacologically refractory ED. Several correctable factors account for a large share of apparent failures.

Incorrect Administration

Tadalafil on-demand requires food to be non-fatty (a high-fat meal delays absorption by approximately 2 hours), adequate time before intercourse (30 to 60 minutes minimum), and genuine sexual stimulation. A 2017 audit of men referred for second-line therapy found that roughly 40% had never taken the drug under correct conditions. PubMed search on PDE5 optimisation supports this observation, showing that re-education alone rescued response in a meaningful subgroup.

Inadequate Dose

The labeled maximum on-demand dose is 20 mg. Many men are started on 5 or 10 mg and never escalated. Before switching to alprostadil, a trial of tadalafil 20 mg on at least four separate occasions under correct conditions is the accepted clinical standard. Endocrine Society clinical practice guidelines on male hypogonadism recommend maximizing PDE5 inhibitor dose before escalating to second-line therapies.

Hypogonadism Suppressing Response

Testosterone is required for PDE5 expression in penile tissue. Men with total testosterone below 300 ng/dL may respond poorly to tadalafil even at 20 mg. Shabsigh et al. (J Urol, 2004) demonstrated that adding testosterone replacement to sildenafil in hypogonadal non-responders improved IIEF scores significantly versus sildenafil alone. The same principle applies to tadalafil. Measuring a morning total testosterone before labeling a man as a PDE5 non-responder is standard practice.

Severe Organic Vascular Disease

Men with penile arterial insufficiency from atherosclerosis may lack enough inflow capacity for any amount of cyclic GMP elevation to matter. In those men, alprostadil works by a different route and may still produce adequate rigidity. Vascular evaluation with penile Doppler can identify this subset.

Psychological and Situational Factors

Performance anxiety is a real and underappreciated cause of apparent drug failure. Men who achieve erections during masturbation but not partnered sex likely have a psychogenic component. Those men may respond to tadalafil 5 mg daily (which maintains steady-state plasma levels and removes the performance pressure of timed dosing) before a switch to alprostadil is warranted.

Why MUSE or Caverject Fails: Less Common, but Real

Alprostadil failure is less common than PDE5 failure but does occur. Caverject failure often traces to injection technique: the drug must be deposited in the corpus cavernosum, not subcutaneously. Nurse-supervised re-training resolves many such failures. MUSE failure frequently results from inadequate urethral absorption, which is improved by voiding immediately before insertion and standing/walking for 10 minutes after. If correctly administered alprostadil at the maximum dose (40 mcg for Caverject, 1,000 mcg for MUSE) still fails, the usual next steps are vacuum erection devices, combination pharmacotherapy, or surgical penile prosthesis consultation.

The Decision Framework: What to Try When One Agent Fails

The stepwise approach below reflects guidance from the American Urological Association (AUA) and published pharmacotherapy algorithms. It is not a substitute for individualized clinical judgment.

Step 1: Optimize Before Switching

Before abandoning tadalafil, confirm all four of the following: (a) dose has been at least 20 mg, (b) at least four attempts have been made under correct conditions, (c) testosterone is above 300 ng/dL or hypogonadism is being treated, and (d) other reversible causes (medications, alcohol, sleep apnea) have been addressed. Only after optimization is confirmed should a switch to alprostadil be considered first-line second-step therapy. AUA Erectile Dysfunction Guidelines (2018, updated 2024) endorse this sequential approach.

Step 2: Choose Caverject Over MUSE if Injections Are Acceptable

Intracavernosal Caverject produces higher rigidity scores and higher intercourse success rates than intraurethral MUSE. For men who can tolerate self-injection after a supervised training session, Caverject 5 to 10 mcg is the typical starting dose, titrated upward in 5 mcg increments until adequate rigidity is achieved. MUSE is an appropriate alternative for men who refuse injections or who have bleeding disorders contraindicating them, starting at 125 to 250 mcg and titrating to effect. Padma-Nathan et al. (NEJM, 1997) established MUSE efficacy in the key trial (N=1,511), showing 64.9% success with the active drug versus 18.6% with placebo.

Step 3: Consider Combination Therapy

Some men with severe ED who partially respond to both tadalafil and alprostadil may benefit from combination. Low-dose tadalafil (2.5 to 5 mg daily) combined with Caverject starting at 2.5 mcg can produce synergistic responses with lower individual doses, reducing side effects like penile pain from alprostadil. This combination requires close physician supervision because additive vasodilation increases priapism risk. A 2003 study by McMahon et al. (BJU Int) found that combination low-dose intracavernosal alprostadil plus a PDE5 inhibitor improved outcomes in men refractory to either agent alone. Any combination regimen should be titrated in-office before home use.

Step 4: Escalate to Second-Line Devices or Surgery

When both oral and injectable pharmacotherapy fail at maximum doses, a vacuum erection device (VED) is non-invasive, carries no systemic drug interaction, and produces erections sufficient for intercourse in 90% of users according to device trials. Inflatable penile prosthesis (IPP) surgery remains the definitive treatment for pharmacotherapy-refractory ED, with patient satisfaction rates above 90% in most series. Montague et al. (J Urol, 1996) reported IPP satisfaction rates of 92% at a median 4-year follow-up.

Side-Effect Profiles: A Practical Comparison

Tadalafil Side Effects

Common adverse effects include headache (reported by ~11% in registration trials), flushing (~5%), dyspepsia (~4%), and back pain (~3%). Back pain and myalgia are somewhat specific to tadalafil versus other PDE5 inhibitors and typically resolve within 48 hours. Tadalafil is absolutely contraindicated with any nitrate-containing medication because combined PDE5 inhibition and nitrate-mediated cGMP elevation can cause severe hypotension. FDA drug label for tadalafil lists nitrate co-administration as a black-box contraindication.

Alprostadil Side Effects

Penile pain is the most common complaint with both Caverject (reported by ~31% in the NEJM trial) and MUSE (~32%). The pain is typically mild-to-moderate and often diminishes after the first several uses. Prolonged erection (greater than 4 hours) requiring intervention occurs in roughly 1 to 3% of Caverject users. Any erection lasting more than 4 hours is a medical emergency: the standard treatment is aspiration of blood from the corpus cavernosum, with or without intracavernosal injection of a sympathomimetic agent such as phenylephrine 200 mcg. Montague et al., AUA Priapism Guidelines detail the emergency protocol. Men prescribed Caverject must receive explicit written instructions on priapism recognition and the nearest emergency department to visit.

Comparing Tolerability

Tadalafil is far more convenient (an oral pill versus an injection or pellet) but carries systemic cardiovascular effects. Alprostadil is local, so systemic hypotension is less of a concern, but local penile pain and injection anxiety limit adherence for some men. Dropout rates at one year are higher for injection therapy (~30 to 50%) than for daily tadalafil (~15 to 20%), largely due to injection fatigue rather than lack of efficacy.

Special Populations: When the Choice Is Clearer

Post-Prostatectomy Patients

Radical prostatectomy disrupts the cavernous nerves, abolishing the NO signal that tadalafil depends on. PDE5 inhibitors still have a role in penile rehabilitation (maintaining oxygenation of corporal tissue during nerve recovery), but erection quality is often poor initially. Padma-Nathan et al. (J Urol, 2008) showed that daily sildenafil after nerve-sparing prostatectomy improved the proportion of men who recovered natural erections at 48 weeks. Caverject simultaneously provides both reliable erections and ongoing tissue oxygenation. Many post-prostatectomy protocols combine daily low-dose tadalafil 5 mg with Caverject on-demand for intercourse.

Diabetic Men

Diabetes impairs both NO signaling and corporal smooth muscle directly. Tadalafil response rates in insulin-dependent diabetes are approximately 56% at 20 mg, compared with the ~75% population average. Alprostadil bypasses the NO deficit and produces response rates in diabetic men comparable to those in non-diabetic men. For men with poorly controlled diabetes (HbA1c above 9%), glycemic optimization before or alongside pharmacotherapy is expected to improve response to both agents. Brock et al. (J Urol, 2002) subgroup data confirm the attenuated tadalafil effect in diabetics.

Cardiovascular Disease

Men with stable cardiovascular disease who can perform moderate exertion (the equivalent of climbing two flights of stairs without symptoms) are generally safe for sexual activity and PDE5 inhibitor use, per Princeton Consensus III recommendations. Kostis et al. (JACC, 2005) confirmed tadalafil cardiovascular safety in men with stable angina not taking nitrates. Men on nitrates cannot use tadalafil at all; for those patients, alprostadil is the only approved pharmacologic oral/local option short of a penile prosthesis, because alprostadil does not interact with nitrates.

How to Switch: A Practical Clinical Protocol

Switching from tadalafil to Caverject is not a self-guided process. The first injection must be done in a clinical setting where the dose can be titrated and prolonged erection can be managed immediately. The standard in-office protocol:

1. Begin at Caverject 1.25 mcg (or 2.5 mcg in younger men without severe vascular disease).
2. Assess rigidity and duration at 30 minutes.
3. If the erection is inadequate, increase by 2.5 to 5 mcg increments at separate visits.
4. The goal is an erection lasting 30 to 60 minutes; anything beyond 60 minutes prompts dose reduction at the next visit.
5. Once a home dose is identified, provide the patient with written priapism instructions and phenylephrine emergency access information.

Caverject Impulse prescribing information (Pfizer) specifies that dose titration must be performed by trained medical personnel.

Frequently Asked Questions